Joint Programming in Neurodegenerative Disease Research (JPND)

Coordinating approaches to research across Europe

Enda ConnollyMember of JPND Executive Board

25/09/2013

We cannot tackle neurodegenerative diseases by acting as single countries

AlbaniaAustriaBelgiumCanadaCroatiaCzech

RepublicDenmarkFinlandFrance

GermanyGreece

HungaryIrelandIsraelItaly

LuxembourgNetherlands

NorwayPoland

PortugalSlovakiaSlovenia

SpainSweden

SwitzerlandTurkeyUnited

Kingdom

JPND is a global research initiative led by EU countries, with 27 participatingEU member statesAssociated countries Third countries

Increasing coordination of national research programmes to improve impact and effectiveness

JPND brings together….

• Researchers (Basic, Clinical, Healthcare/Social)

• National Funding Bodies

• National Research Strategies and Investments

• Current JPND strategy:• To increase coordinated investment in ND research aimed at finding

causes of disease, developing cures, and identifying appropriate ways to care for those with neurodegenerative diseases

• Immediate JPND goals:• To add value to national investments through coordinated action• To encourage the development of national research strategies in ND• To engage in partnership to reach the full potential of JPND

JPND currently partly - supported by FP7-JUMPAHEAD (GA. 260774)

Management Board • 27 countries represented• Members mandated to act• Chair Philippe Amouyel - France

Executive Board• Vice-Chair Adriana Maggi - Italy • Enda Connolly - Ireland • Edvard Beem - Netherlands • Mogens Horder - Denmark

Scientific Advisory Board• 18 Members, chosen for scientific

excellence and competence

Organisation

Steering Committee• Executive Board

+ Rob Buckle - UK+ Rainer Girgenrath - Germany

Societal Needs

Creative research

(Idea Generation)

Innovation(Idea Implementation)

• 27 JPND Members

• Member States

• Assoc. Countries

• Third Countries

• Eur. Commission

• Industry

• Public and Users

• Common Strategy

• Transnational Calls

• Alignment Actions

• National Plans

• Communication and

Dissemination

• New treatments +

preventive strategies

• Improved health + social

care approaches

• De-stigmatize ND

• Alleviate economic and

social burden

PARTNERSHIP ACTIONS OUTCOMES

JPND Research

Basic Clinical Healthcare/Social

European Research Landscape

• Greatest amount of funds are available through national government budgets:• 2011 Total ND Research Funding: 1.621 Billion*

• Basic research: 1.362 Billion• Clinical research: 183 Million• Healthcare/Social Research: 76 Million

• JPND Research Strategy Goals• To develop new treatments and preventive strategies• To improve health and social care approaches• To raise awareness and de-stigmatise neurodegenerative disorders• To alleviate the economic and social burden of these diseases

* Alzheimer’s disease and other dementias (AD)Parkinson’s disease (PD) and PD-related disorders Prion diseaseMotor neurone diseases (MND)

Huntington’s disease (HD)Spinocerebellar ataxia (SCA)Spinal muscular atrophy (SMA)

How can JPND reach its goals?

• Alignment of research in Member Countries

• Partnership with European Commission

• Partnership with Industry

• Partnership with other international organisations

• Involvement of Patients and Public

Why is AAL important to JPND?

• Priority in JPND Research Strategy• Enormous potential in the development of effective measures

for prevention, intervention and care for people with ND/dementia and their (in)formal carers

• AAL JP • ~25% of current projects are developing ICT-based solutions

for support and care of older adults with cognitive impairments; • Monitoring and surveillance • Orientation• Localisation• Guidance by (informal) carers

Joining forces

• Objectives of JPND - AALJP Engagement

• To agree on a common research agenda• To align research priorities for ND• To determine how to implement priorities through partnership

• Objectives of Future Joint Workshop

• To bring together important stakeholders in this area • users, academia, small businesses, ICT and service industry

• To share knowledge on JPND and AAL JP• To identify gaps and potential benefits of collaboration• To recommend future joint actions and opportunities

Next Steps…..Stakeholder Workshop

• Identify areas of common interest – “mini-SRA”

• Report delivered to JPND and AAL

• Action Group to prioritize actions to be taken

Draft Agenda:• Introduction/Plenary + Parallel Subgroup Breakouts

• Sub-Groups: User Needs , Marketability Aspects, Setting Standards

• Presentation and discussion of case studies

• Identification of 5-6 priority issues to be addressed per area

• Discussion on recommendations, leading to overarching report

JPND – AAL JP Action Group

Name Affiliation

Enda Connolly Health Research Board, IE

Jacqueline Hoogendam Ministry of Health, Welfare and Sport, NL

Rafael de Andres ISCIII, ES

Derick Mitchell JPND

Karina Marcus AAL JP Central Management Unit

Geja Langerveld ZonMw, NL

Pietro de Siciliano Institute for Microelectronics and Microsystems, IT

Keep up to date

• Visit the JPND website:• http://www.neurodegenerationresearch.eu• http://www.jpnd.eu

• Search our Mapping Database

• Sign up to the JPND News Feeds

• E-mail us: secretariat@jpnd.eu

• Follow us on Twitter:

@JPNDEurope